Stay updated on Pembrolizumab & Lanreotide for GI NETs Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page.

Latest updates to the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page
- CheckyesterdayChange DetectedAdded a site-wide notice about possible delays due to funding, and updated the page revision to v3.4.1. The previous revision was v3.4.0.SummaryDifference0.4%

- Check8 days agoChange DetectedUI updates include a new 'Show glossary' option and minor text changes such as capitalization of labels and an updated revision/version to v3.4.0. No substantive study content, outcomes, or eligibility details were altered.SummaryDifference0.2%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page shows an administrative revision label: v3.3.4, replacing the previous v3.3.3. No core study content, eligibility criteria, locations, or outcomes were changed.SummaryDifference0.1%

- Check44 days agoChange DetectedAdded a Locations section listing North Carolina (Duke University Medical Center, Durham) and South Carolina (Columbia and Lexington Medical Center) study sites, replacing the prior separate state location headings; removed the HHS Vulnerability Disclosure link in the footer as part of Revision: v3.3.3.SummaryDifference0.3%

- Check72 days agoChange DetectedThe page footer revision label was updated from v3.2.0 to v3.3.2, indicating a minor update to the page metadata. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check79 days agoChange DetectedRemoval of the government funding notice banner at the top of the ClinicalTrials.gov study page.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab & Lanreotide for GI NETs Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page.